- Home
- GILD vs TD Comparison
GILD vs TD Comparison
Compare GILD & TD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | TD |
|---|---|---|
| Founded | 1987 | 1855 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0B | 195.5B |
| IPO Year | 2003 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GILD | TD |
|---|---|---|
| Price | $146.55 | $117.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $148.39 | $120.00 |
| AVG Volume (30 Days) | ★ 6.4M | 1.6M |
| Earning Date | 05-07-2026 | 05-21-2026 |
| Dividend Yield | 2.55% | ★ 2.95% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.68 | N/A |
| Revenue Next Year | $6.04 | $4.48 |
| P/E Ratio | ★ N/A | $11.65 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $108.46 | $72.73 |
| 52 Week High | $157.29 | $125.47 |
Technical Indicators
Market Signals| Indicator | GILD | TD |
|---|---|---|
| Relative Strength Index (RSI) | 68.47 | 41.79 |
| Support Level | $142.93 | $117.08 |
| Resistance Level | $149.38 | $125.17 |
| Average True Range (ATR) | 3.50 | 1.83 |
| MACD | 1.12 | -0.71 |
| Stochastic Oscillator | 91.85 | 23.01 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets by the end of April 2026. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market shares in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.